Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
35301507 2022 LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature cancer Likely relevant The study evaluates Lcor mRNA therapy in combination with anti-PD-L1 in preclinical models, measuring tumor immunogenicity and antigen presentation machinery. immune-checkpoint blockade; anti-PD-L1; extracellular vesicle Lcor-messenger RNA therapy Mixed triple-negative breast cancer immune-checkpoint blockade 0/0/0; anti-PD-L1 0/15/0; extracellular vesicle Lcor-messenger RNA therapy 0/0/0 Awaiting curator check
35314795 2022 CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. British journal of cancer Likely relevant The study tests anti-PD-L1 therapy in murine ovarian cancer models and measures cellular immune composition and T-cell accumulation. anti-PD-L1 Animal ovarian cancer anti-PD-L1 0/15/0 Awaiting curator check
35322234 2022 Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature Likely relevant The study demonstrates that androgen receptor blockade and PD-1 targeted therapy in tumour-bearing hosts enhance CD8 T cell function and IFNγ expression while preventing T cell exhaustion. PD-1 targeted therapy; androgen deprivation therapy Animal prostate cancer PD-1 targeted therapy 0/0/0; androgen deprivation therapy 0/0/0 Awaiting curator check
35364611 2022 Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer. Molecular cancer therapeutics Likely relevant The study tests a novel bispecific antibody (LY6G6D-TDB) alone and combined with PD-1 blockade in vitro and in mouse xenograft models, measuring T-cell activation and cytotoxicity. LY6G6D-TDB; anti-PD-1 Mixed colorectal cancer LY6G6D-TDB 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
35392977 2022 Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Journal of experimental & clinical cancer research : CR Likely relevant The study experimentally tests a bio-nanoparticle vaccine combined with PD-1 blockade in murine models and measures extensive immune cell expansions and shifts. λ phage vaccine; PD-1 inhibitor Animal triple negative breast cancer and hepatocellular carcinoma λ phage vaccine 0/0/0; PD-1 inhibitor 0/0/0 Awaiting curator check
35524267 2022 Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer. Journal of nanobiotechnology Likely relevant Tests a nanoparticle-delivered combination of anti-PD-L1 and V9302 in mice and measures CD8+ T cell infiltration, activation, and cytokine levels. anti-PD-L1 antibody; V9302 Animal triple-negative breast cancer anti-PD-L1 antibody 0/1/0; V9302 0/0/0 Awaiting curator check
35567985 2022 Rejuvenating hepatic tumor microenvironment immunity with a phosphatidylserine-targeting small molecule drug conjugate. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant Tests a small molecule drug conjugate in a mouse model and measures immune cell infiltration, granzyme B, and inflammation-related gene expressions. conjugate 16b; sorafenib Animal hepatocellular carcinoma conjugate 16b 0/0/0; sorafenib 27/25/7 Awaiting curator check
35577503 2022 Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant The study evaluates combination treatment with emactuzumab and atezolizumab in advanced solid tumor patients and measures changes in CD8+ TILs and TAMs. emactuzumab; atezolizumab Patient advanced solid tumors emactuzumab 0/0/0; atezolizumab 0/0/4 Awaiting curator check
35580929 2022 CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer Likely relevant The study tests a vaccination strategy combined with PD-1/PD-L1 immunotherapy in mouse models and measures its effects on T cell responses. anti-PD-1; anti-PD-L1 Animal melanoma and colorectal adenocarcinoma anti-PD-1 14/36/0; anti-PD-L1 0/15/0 Awaiting curator check
35584676 2022 WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports Likely relevant The study experimentally tests WEE1 inhibition and PD-L1 blockade in SCLC animal models and measures immune readouts including T cell infiltration and cytokine expression. AZD1775; PD-L1 blockade Animal small cell lung cancer AZD1775 5/5/0; PD-L1 blockade 0/4/0 Awaiting curator check
35610387 2022 Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. Cancer immunology, immunotherapy : CII Likely relevant The study tests a combination of therapies including cisplatin, STING agonist, and ICIs in tumor-bearing mice, measuring T cell populations and cytokine levels. cisplatin; tumor-specific peptide; neoantigen; DMXAA; immune checkpoint inhibitor Animal unspecified cancer cisplatin 18/3/11; tumor-specific peptide 0/0/0; neoantigen 0/0/0; DMXAA 0/0/0 Awaiting curator check
35781395 2022 Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. Journal for immunotherapy of cancer Likely relevant The study tests intravesical bacterial immunotherapy and anti-PD-L1 in an orthotopic mouse model and measures T-cell responses and dendritic cell activation. MTBVAC; BCG; anti-PD-L1 Animal bladder cancer MTBVAC 0/0/0; BCG 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
35793868 2022 Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. Journal for immunotherapy of cancer Likely relevant The study tests an SCD1 inhibitor and anti-PD-1 antibody in mouse tumor models and measures their effects on antitumor T cell responses and dendritic cell recruitment. SCD1 inhibitor; anti-PD-1 antibody Animal colon cancer and non-small cell lung cancer SCD1 inhibitor 0/0/0; anti-PD-1 antibody 0/2/0 Awaiting curator check
35802648 2022 PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. Cancer research Likely relevant The study tests PIM2 kinase inhibition and IL1β blockade combined with ICB in vivo and measures effects on T-cell cytotoxicity and tumor inflammation. immune checkpoint blockade; IL1β blockade; PIM2 kinase inhibitor Animal hepatocellular carcinoma immune checkpoint blockade 0/1/0; IL1β blockade 0/0/0; PIM2 kinase inhibitor 0/0/0 Awaiting curator check
35920742 2022 Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant The article experimentally tests an LSD1 inhibitor (bomedemstat) and anti-PD-1 therapy in mouse and human models, measuring effects on CD8+ T-cell infiltration, MHC-I expression, and tumor cell killing. bomedemstat; anti-PD-1 Mixed small cell lung cancer bomedemstat 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
35925680 2022 Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. The Journal of clinical investigation Likely relevant Investigates miR-155 overexpression in breast cancer cells combined with immune checkpoint blockade in mice, measuring T cell influx and cytokine production. immune checkpoint blockade Animal breast cancer immune checkpoint blockade 0/1/0 Awaiting curator check
35926754 2022 Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study tests Camptothesome in colorectal cancer models and measures immunogenic cell death hallmarks and overall immune responses. Camptothesome; camptothecin; Onivyde; immune checkpoint inhibitors Animal colorectal cancer Camptothesome 0/0/0; camptothecin 5/0/0; Onivyde 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
35929803 2022 Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer discovery Likely relevant The study evaluates the immunomodulatory effects of the anticancer drug pembrolizumab in bladder cancer patients and reports immune readouts such as TFH cells and CXCL13. pembrolizumab Patient bladder cancer pembrolizumab 0/0/16 Awaiting curator check
36037718 2022 Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma. Journal of colloid and interface science Likely relevant The study experimentally tests a multifunctional nanoplatform delivering doxorubicin and indocyanine green combined with PD-1 blockade in mice with hepatocellular carcinoma and measures various immune parameters. doxorubicin; indocyanine green; PD-1 blockade Animal hepatocellular carcinoma doxorubicin 22/9/0; indocyanine green 1/2/0; PD-1 blockade 0/0/0 Awaiting curator check
36050478 2022 Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. Cellular & molecular immunology Likely relevant The study evaluates anti-PD-1 monoclonal antibody treatment in immunocompetent melanoma mouse models and tumor T-cell cocultures, measuring its effects on antitumor immunity. anti-PD-1 monoclonal antibody Animal melanoma anti-PD-1 monoclonal antibody 0/0/0 Awaiting curator check
36067356 2022 Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy. Journal of medicinal chemistry Likely relevant The study experimentally tests cyclic anti-PD-L1 peptides in vivo and evaluates PD-1/PD-L1 blocking activity. cyclic anti-PD-L1 peptides Animal cancer cyclic anti-PD-L1 peptides 0/0/0 Awaiting curator check
36083892 2022 The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Science immunology Likely relevant The study experimentally tests the microbial metabolite TMAO alone and combined with checkpoint inhibitors in tumor-bearing mice, measuring macrophage polarization and T cell activation. trimethylamine N-oxide; anti-PD1; anti-Tim3 Animal pancreatic ductal adenocarcinoma trimethylamine N-oxide 0/0/0; anti-PD1 1/1/0; anti-Tim3 0/0/0 Awaiting curator check
36096533 2022 Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. Journal for immunotherapy of cancer Likely relevant The study tests an anti-GARP antibody alone and with anti-PD-1 in murine models, evaluating its effects on TGFbeta signaling, T cell exhaustion, and CD8+ T cell trafficking. PIIO-1; anti-PD-1 Animal cancer (general) PIIO-1 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
36113478 2022 Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer cell Likely relevant The study experimentally tests imipramine and VEGF pathway inhibitors, along with anti-PD-L1, in GBM mouse models and measures their effects on T cell infiltration/activation and macrophage reprogramming. imipramine; anti-programmed death-ligand 1 (PD-L1) Animal glioblastoma imipramine 0/0/0; anti-programmed death-ligand 1 (PD-L1) 0/0/0 Awaiting curator check
36113897 2022 HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. Journal for immunotherapy of cancer Likely relevant The study experimentally tests recombinant HSP90alpha on human monocytes and measures its effects on PD-L1, HLA-DR, and T cell suppression. recombinant HSP90alpha Mixed melanoma recombinant HSP90alpha 0/0/0 Awaiting curator check
← Previous Page 12 of 15 Next →